Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs

Rhea-AI Summary

Proteovant Therapeutics, a company under Roivant Sciences (ROIV), has achieved significant milestones by nominating PVTX-321 and PVTX-405 as development candidates. These drugs target previously challenging proteins, with PVTX-321 showing impressive tumor growth inhibition in preclinical models and PVTX-405 demonstrating robust IKZF2 degradation. The company will present these findings at major upcoming conferences in Boston and London. This progress in the development pipeline reflects Proteovant's commitment to advancing therapeutic options for patients with life-altering diseases.

Positive

• PVTX-321 demonstrates impressive tumor growth inhibition in preclinical models.
• PVTX-405 shows best-in-class potential for IKZF2 degradation.
• Proteovant's pipeline includes heterobifunctional degraders and molecular glues targeting unmet medical needs.

Negative

• None.

PVTX-321 and PVTX-405 Achieve Development Candidate Nomination

NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Proteovant Therapeutics, a Roivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases, today announced it will present data on PVTX-321, an estrogen receptor degrader, at the Protein Degradation & Targeting Undruggables Congress USA, March 15-16 in Boston and on PVTX-405, an IKZF2 molecular glue, at the Targeted Protein Degradation Europe Conference, March 28-30 in London.

Targeted protein degradation harnesses the body’s natural protein disposal system and offers the potential to develop new medicines targeting historically difficult-to-drug proteins that play an important role in causing serious diseases. Proteovant Therapeutics is discovering and developing best-in-class and first-in-class degraders that can engage previously undruggable targets.

“We are advancing a robust pipeline of heterobifunctional degraders and molecular glues that span a range of novel molecular targets, which are implicated in disorders where new medicines are needed,” said Drew Fromkin, CEO, Proteovant Therapeutics. “PVTX-321, our degrader targeting the estrogen receptor, is highly potent and demonstrates impressive, dose dependent tumor growth inhibition and shrinkage in preclinical models. In addition, PVTX-405 has best-in-class potential with robust IKZF2 degradation in vivo. We are enthusiastic about the progress being made across our degrader pipeline and molecular glue platform initiatives.”

Presentation at Protein Degradation & Targeting Undruggables Congress USA

• Title: Discovery and Characterization of an Estrogen Receptor Heterobifunctional Degrader with Best In-Class Potential
  • Session Time: 12:00-12:25 p.m. EDT on March 15, 2023
  • Presenter: Courtney Havens, Director, Biology, Proteovant Therapeutics
    

Presentation at Targeted Protein Degradation Europe Conference

• Title: Discovery and Characterization of an IKZF2 Selective Molecular Glue Degrader with Best In-Class Potential
  • Session Time: 4:30 p.m. BST on March 29, 2023
  • Presenter: Harshil Dhruv, Associate Director, Biology, Proteovant Therapeutics
    

Following the presentations at each event, materials will be made available online here.

About Proteovant Therapeutics
Proteovant Therapeutics exploits the ubiquitin-protease system (UPS) to discover and develop transformative medicines for the treatment of patients with life-altering diseases. Protein degradation harnesses the human body’s innate cellular machinery by way of the UPS to identify and mark disease causing proteins for destruction. This promising approach provides the opportunity to target proteins of interest, many of which were previously considered undruggable. Proteovant integrates its degrader drug hunting expertise, MOPED™ molecular glue screening platform, and external partnerships to advance novel protein degraders across a range of therapeutic areas. Founding investors include Roivant Sciences (Nasdaq: ROIV) and SK Inc. Visit www.proteovant.com and follow us on LinkedIn.

Media Contact
Liz Boten
Liz.Boten@canalecomm.com
Evoke Canale for Proteovant Therapeutics

 

FAQ

What is the purpose of PVTX-321 developed by Roivant Sciences?

PVTX-321 is an estrogen receptor degrader aimed at inhibiting tumor growth.

What are the implications of PVTX-405 for cancer treatment?

PVTX-405 is a molecular glue that targets IKZF2, potentially offering a new treatment avenue.

When will data on PVTX-321 be presented?

Data on PVTX-321 will be presented on March 15, 2023, at the Protein Degradation & Targeting Undruggables Congress in Boston.

What event is PVTX-405 being presented at?

PVTX-405 will be presented at the Targeted Protein Degradation Europe Conference from March 28-30, 2023, in London.

How does Proteovant Therapeutics develop its drugs?

Proteovant utilizes the ubiquitin-protease system to target and degrade disease-causing proteins.